Hematopoietic stem cells (HSCs) have the ability to self-renew and differentiate into all blood cell lineages and are critical for maintaining the homeostasis of the hematopoietic system. HSCs exist predominantly in a quiescent state 1 , which is critical for preservation of self-renewal capacity and enablement of life-long hematopoiesis 2 . Elucidating the molecular regulation of HSC quiescence should increase the understanding of mechanisms important for tissue regeneration and might indicate how these become dysregulated in pathological conditions. The quiescent state of HSCs is tightly controlled by both intrinsic molecular mechanisms and extrinsic signals from the microenvironment. Several cell-cycle regulators, as well as molecules with functions in the regulation of oxidative stress, transcriptional regulation of hematopoiesis, or chromatin modification, have been shown to regulate HSC quiescence by intrinsic mechanisms 3, 4 .
A r t i c l e s
Hematopoietic stem cells (HSCs) have the ability to self-renew and differentiate into all blood cell lineages and are critical for maintaining the homeostasis of the hematopoietic system. HSCs exist predominantly in a quiescent state 1 , which is critical for preservation of self-renewal capacity and enablement of life-long hematopoiesis 2 . Elucidating the molecular regulation of HSC quiescence should increase the understanding of mechanisms important for tissue regeneration and might indicate how these become dysregulated in pathological conditions. The quiescent state of HSCs is tightly controlled by both intrinsic molecular mechanisms and extrinsic signals from the microenvironment. Several cell-cycle regulators, as well as molecules with functions in the regulation of oxidative stress, transcriptional regulation of hematopoiesis, or chromatin modification, have been shown to regulate HSC quiescence by intrinsic mechanisms 3, 4 .
Foxm1 belongs to the large family of Fox ('Forkhead box') transcription factors. It is a key regulator of aspects of the transition from G1 phase to S phase in the cell cycle, progression through S phase, transition from G2 phase to M phase, and progression through M phase 5 , and is critical for DNA replication, mitosis 6 and genomic stability 7 . Foxm1 has pleiotropic roles during embryonic development and tissue regeneration after injury 5 . Foxm1 is broadly expressed in embryonic tissues, while its expression in adult mice is restricted to the testes, thymus and intestinal crypts [8] [9] [10] . However, Foxm1 expression is reactivated after organ injury 5, 11 . Studies have demonstrates that Foxm1 has a role in the proliferation of hepatocytes and pancreatic endocrine cells during liver and pancreatic regeneration 12, 13 . Consistent with a critical role for Foxm1 in cell-cycle progression, increased expression of FOXM1 has been found in various human tumors, including lung cancer, breast cancer, liver cancer, glioblastoma and pancreatic cancer 14 . Collectively, Foxm1 has been considered a proliferation-specific transcription factor required for cellular proliferation in various tissues. However, little is known of the function of Foxm1 during hematopoiesis. Deletion of Foxm1 during T cell lymphopoiesis reduces the proliferation of early thymocytes and activates mature T cells but does not affect T cell differentiation 15 , while deletion of Foxm1 in the myeloid lineage does not affect the proliferation or differentiation of myeloid cells 16 . Notably, the effects of loss of Foxm1 in HSCs or hematopoietic progenitor cells (HPCs) have not been examined.
Here we investigated the function of Foxm1 in HSCs and HPCs through the use of mouse models with conditional deficiency in Foxm1. We found that loss of Foxm1 reduced the frequency of quiescent HSCs and increased the proliferation of both HSCs and HPCs but did not affect the differentiation of HSCs or HPCs. As a consequence, Foxm1-deficient HSCs had significantly lower self-renewal capacity than that of Foxm1-sufficient HSCs. Mechanistically, loss of Foxm1 induced downregulation of cyclin-dependent kinase inhibitors, including p21 and p27, by directly suppressing the expression of the gene encoding Nurr1 (Nr4a2; called 'Nurr1' here), a critical regulator of HSC quiescence 17 . Notably, reducing expression of FOXM1 in human CD34 + primitive hematopoietic cells also decreased quiescence, and database analysis revealed that the expression of both FOXM1 and NURR1 was significantly downregulated in CD34 + cells from a subset of patients with myelodysplastic syndrome (MDS). Together our data provide evidence that Foxm1 is a critical regulator of the quiescence and self-renewal capacity of HSCs through Nurr1-mediated pathways.
RESULTS

Altered hematopoiesis in Foxm1-deficient mice
A function for Foxm1 in HSCs and HPCs has not been reported before, to our knowledge. To determine its role, we characterized the expression of Foxm1 in subsets of primitive and mature bone marrow (BM) cells. Foxm1 had higher expression in primitive hematopoietic cells than in differentiated cells, including mature Mac-1 + Gr-1 + myeloid cells, B220 + B cells, CD71 + Ter119 + erythroblasts, and CD4 + or CD8 + T cells (Fig. 1a) . Notably, Foxm1 had higher expression in long-term HSCs (LT-HSCs: Lin − Sca-1 + c-Kit + CD48 − CD150 + ) than in LSK (Lin − Sca-1 + c-Kit + ) cells or HPCs (Lin − c-Kit + Sca-1 − ), which suggested an important role for Foxm1 in HSCs.
To investigate the in vivo function of Foxm1 in normal hematopoiesis, we crossed mice with loxP-flanked Foxm1 alleles (Foxm1 fl/fl ) 11 with Tie2-Cre mice, in which a transgene encoding Cre recombinase is expressed in endothelial cells and HSCs under the control of the Tie2 promoter 18, 19 , to generate control Foxm1 fl/fl mice and Foxm1 fl/fl Tie2-Cre mice, with conditional deletion of Foxm1 (called 'Foxm1-CKO mice' here). We confirmed high efficiency of Foxm1 deletion in BM and LSK cells by semiquantitative PCR analysis of genomic DNA isolated from BM cells (Supplementary Fig. 1a ) and LSK cells (Fig. 1b) from Foxm1-CKO and Foxm1 fl/fl mice. Accordingly, quantitative PCR analysis showed only trace amounts of Foxm1 mRNA in BM cells (Supplementary Fig. 1b ) and LSK cells (Fig. 1c) from Foxm1-CKO mice. We analyzed the key hematological parameters in these mice at 6 weeks of age. Foxm1-CKO mice had considerably fewer white blood cells, neutrophils, lymphocytes, monocytes and platelets than did their Foxm1 fl/fl littermates (Fig. 1d) . The total number of BM cells was lower in Foxm1-CKO mice than in their Foxm1 fl/fl control littermates (Fig. 1e) , with some Foxm1-CKO mice showing distinctly hypocellular BM (Supplementary Fig. 1c) . Likewise, flow cytometry revealed that the total number of mature myeloid cells, B cells, CD41 + megakaryocytes and F4/80 + macrophages was also lower in BM from Foxm1-CKO mice than in that of their Foxm1 fl/fl control littermates (Supplementary Fig. 2a) . However, the frequency of these mature blood cells in BM was similar for Foxm1-CKO mice and Foxm1 fl/fl control mice (Supplementary Fig. 2b-e) , which suggested that loss of Foxm1 did not affect the differentiation of myeloid cells or B cells under homeostatic conditions in young mice. Loss of Foxm1 did not interfere with differentiation of the erythroid lineage. We detected a similar frequency of erythroid blasts in four stages of mouse erythroid differentiation 20 in both the BM and spleen of Foxm1-CKO mice and Foxm1 fl/fl control mice ( Supplementary Fig. 2f-i) . Thus, our data indicated that deletion of Foxm1 led to ineffective hematopoiesis but did not affect the differentiation of mature blood cells.
Cell-intrinsic control of HSC and HPC pools by Foxm1
During normal hematopoiesis, LT-HSCs have ability to self-renew, with the potential for differentiation into common myeloid progenitors (CMPs) and more-committed myeloid progenitor cells, including granulocyte-monocyte progenitors (GMPs) and megakaryocyteerythroid progenitors (MEPs) 21 . We hypothesized that the abnormal hematopoiesis observed in Foxm1-CKO mice was probably a consequence of an alteration in HSCs and/or HPCs. We thus examined these compartments by flow cytometry. We observed that both the frequency and the total number of LSK cells, a stem cell-enriched population, were significantly lower, by fivefold to sixfold, in Foxm1-CKO mice than in Foxm1 fl/fl control mice (Fig. 2a,b) . In addition, the total number of CD34 − LSK cells or LT-HSCs was also significantly lower in Foxm1-CKO mice (Fig. 2a,b) . We also noted that both the frequency of HPCs and total number of HPCs were 50% lower in Foxm1-CKO mice (Fig. 2a,d) .
We next characterized myeloid progenitor cells in Foxm1-CKO and Foxm1 fl/fl mice. The frequency of CMPs was significantly lower in Foxm1-CKO mice than in Foxm1 fl/fl mice, while Foxm1-CKO and Foxm1 fl/fl mice had a similar frequency of GMPs and MEPs cells in vivo (Fig. 2c) . However, the total number of all these subsets of myeloid progenitors was lower in Foxm1-CKO mice than in Foxm1 fl/fl mice (Fig. 2d) . A pool of lymphoid-primed multipotent progenitors (LMPPs: Lin − Sca-1 + c-Kit + Flt3 + ) has been identified with the ability to generate B cells, T cells and monocytes 22 . Foxm1-CKO mice had a significantly lower absolute number of LMPPs than did Foxm1 fl/fl mice (Fig. 2e) . We determined the frequency of myeloid progenitors in BM from Foxm1-CKO and Foxm1 fl/fl mice by in vitro colony-forming unit A r t i c l e s npg A r t i c l e s assays. We plated a similar number of BM cells isolated from Foxm1 fl/fl or Foxm1-CKO mice in methylcellulose medium containing interleukin 3 (IL-3), IL-6, stem-cell factor and erythropoietin and cultured the cells for 10-12 d. Foxm1-deficient BM cells (from Foxm1-CKO mice) gave rise to markedly lower numbers of total colony-forming units, as well as colony-forming units of a variety of myeloid precursors, including granulocyte-erythroid-macrophage-megakaryocyte colonies, granulocyte-macrophage colonies, granulocyte colonies, macrophage colonies and burst-forming unit-erythroid colonies, than did Foxm1 fl/fl BM cells (Fig. 2f) .
Endothelial cells constitute a critical niche for HSCs [23] [24] [25] . To rule out the possibility that the endothelial niche that HSCs are exposed to during development caused the observed hematopoietic defects in Foxm1-CKO mice, we crossed Foxm1 fl/fl mice with Mx1-Cre mice (which express Cre under the control of the interferon-inducible Mx1 promoter) to generate Foxm1 fl/fl Mx1-Cre mice, in which deletion of Foxm1 in the hematopoietic compartments is efficiently induced in adult mice by intraperitoneal injection of the interferon-α inducer polyinosinic-polycytidylic acid (poly(I:C)) into adult mice ( Supplementary Fig. 3a,b) . Following induction of the deletion of Foxm1, Foxm1 fl/fl Mx1-Cre mice had a reduced number of total BM cells (Supplementary Fig. 3c ) and developed a defect in the HSC compartment similar to that observed in Foxm1-CKO mice (Fig. 2g,h (Fig. 2g) and a concomitant reductions in the number of HPCs, CMPs and LMPPs (Fig. 2h,i) . Together these data suggested that loss of Foxm1 significantly interfered with the maintenance of adult HSCs and early HPCs during normal hematopoiesis and that the defect seemed to be independent of the endothelial niche.
However, Cre expressed from the Mx1-Cre transgene also induces gene deletion in non-hematopoietic cells, including the BM stromal compartment and liver 26 . To rule out the possibility that the effects of Foxm1 deletion on HSCs and HPCs were dependent on the BM microenvironment, we transplanted BM cells from Fig. 4a ). We induced deletion of Foxm1 in the chimeric Foxm1 fl/fl Mx1-Cre mice by injection of poly(I:C) 6 weeks after transplantation and, 2 months later, we assessed the HSC and Fig. 4b ). In addition, the number of HPCs and CMPs was also significantly lower in the Foxm1 fl/fl Mx1-Cre chimeric mice (Supplementary Fig. 4c ). In summary, our results indicated that Foxm1 was an intrinsic regulator of HSCs and HPCs.
Loss of Foxm1 impairs the long-term self-renewal of HSCs
To further investigate the effects of the deletion of Foxm1 on hematopoietic reconstitution in situ in primary mice, we gave Foxm1-CKO and Foxm1 fl/fl mice weekly injections of the cell cycle-dependent myelotoxic agent 5-fluorouracil (5-FU) 27 , which kills proliferating cells, including HPCs, and thus stimulates HSCs to proliferate and replenish the hematopoietic system. We monitored the treated mice for up to 3 weeks. 80% of Foxm1-deficient mice succumbed after the second injection of 5-FU, and all remaining mice died after a third injection of 5-FU (Fig. 3a) . In contrast, more than 90% of control mice were still alive after the third injection of 5-FU (Fig. 3a) . Analysis of BM cells and HPCs from another cohort of 5-FU-treated Foxm1-CKO and Foxm1 fl/fl mice indicated that Foxm1-deficient HSCs failed to efficiently replenish BM cells and HPCs (Fig. 3b,c) .
To further evaluate the long-term self-renewal capacity of Foxm1-deficient HSCs, we performed serial BM-transplantation assays. We obtained BM cells (5 × 10 6 ) from two to three Foxm1-CKO or Foxm1 fl/fl mice and serially transplanted the cells into lethally irradiated wild-type recipients. While Foxm1 fl/fl HSCs ceased to reconstitute the lethally irradiated mice after the fourth transplantation cycle, Foxm1-CKO HSCs failed to reconstitute hematopoiesis after secondary transplantation (Fig. 3d) , which suggested that Foxm1-deficient HSCs had a considerable defect in their self-renewal capacity.
Next we assessed the reconstituting capacity of Foxm1-deficient HSCs in a competitive environment by performing competitive serial transplantation assays. We transplanted an equal number of BM cells or sorted LT-HSCs from A r t i c l e s a progressive repopulation defect, with 80% less repopulation than that of Foxm1 fl/fl cells at 1 month after primary transplantation and 90% less repopulation at 4 months (Fig. 4a, left) . Purified Foxm1-deficient LT-HSCs also showed a progressive decrease in repopulation capacity, with 25% less repopulation than that of Foxm1 fl/fl LT-HSCs at 1 month after transplantation and 90% less at 4 months (Fig. 4a) . Peripheral blood cells derived from Foxm1-deficient BM cells and LT-HSCs were barely detectable at 4 months after the second transplantation (Fig. 4a) .
We also performed competitive repopulation assays with BM cells from Foxm1 fl/fl Mx1-Cre and Foxm1 fl/fl mice. Without induction of Foxm1 deletion by poly(I:C), Foxm1 fl/fl Mx1-Cre and Foxm1 fl/fl BM cells had a similar repopulation capacity (Fig. 4b) . Delayed deletion of Foxm1 induced at 6 weeks after transplantation consistently resulted in a progressive decrease in HSC repopulation capacity (Fig. 4b) . Flow cytometry of total mature cells (Fig. 4c) and of the myeloid, B cell and T cell lineages in peripheral blood (Supplementary Fig. 5a-c) revealed that the repopulation of all three lineages was impaired. Additionally, immature BM cells derived from Foxm1-deficient donor cells were barely detectable at 4 months after the second transplantation ( Fig. 4d and Supplementary Fig. 5d,e) , indicative of an HSC defect. Consistent with the data obtained with Foxm1-CKO mice, loss of Foxm1 did not affect lineage differentiation during the repopulation of hematopoietic cells in recipient mice (Supplementary Fig. 5f ). In summary, these studies provided evidence that loss of Foxm1 exerted a negative effect on the long-term regenerative capacity of HSCs.
Foxm1 deficiency increases the cycling of HSCs and HPCs
Published findings indicate that Foxm1 has a role in the G1-to-S cell-cycle transition [28] [29] [30] and also contributes to regulation of the G2-to-M transition in mammalian cells 7, 29 . As Foxm1 is a critical cellcycle regulator, we investigated whether loss of Foxm1 would lead to cell-cycle defects in HSCs and HPCs. We observed a greater accumulation of cells in the S phase and G2-M phase among Foxm1-deficient HPCs, LSK cells and LT-HSCs (from Foxm1-CKO mice) than among their counterparts from control (Foxm1 fl/fl ) mice (Fig. 5a-c) .
To determine whether the accumulation of cells in the S and G2-M phases among Foxm1-deficient LSK cells and LT-HSCs was due to the block of the cell cycle in S phase and the G2-to-M transition or to an overall increase in cycling cells, we assessed in vivo incorporation of the thymidine analog BrdU to investigate the cell-cycle kinetics of LSK cells and LT-HSCs from Foxm1-CKO and Foxm1 fl/fl mice. While ~13% of Foxm1 fl/fl LSK cells (and ~5% of Foxm1 fl/fl LT-HSCs) incorporated BrdU, ~50% of the Foxm1-CKO LSK cells (and ~35% of Foxm1-CKO LT-HSCs) were BrdU + (Fig. 5d,e) , which indicated that the absence of Foxm1 enhanced the proliferation of LT-HSCs and LSK cells. In addition, loss of Foxm1 also led to the accumulation of cells at the G2-to-M transition among LT-HSCs and LSK cells (Fig. 5d,e) . Collectively, our studies suggested that Foxm1 regulated the cell cycle in a context-dependent manner.
As quiescence is crucial for the function of HSCs, we next determined the fraction of the stem cell-enriched population (LSK cells) in G0 by assessing RNA and DNA content through the use of staining Fig. 5f) , which suggested that Foxm1 deficiency regulated the G0 phase in HSCs. Similarly, deletion of Foxm1 induced by Cre expressed from Mx1-Cre resulted in a loss of G0 maintenance in LSK cells and defects in cell-cycle progression in HSCs, LSK cells and HPCs in both primary and chimeric mice (Supplementary Fig. 6 ). Thus, these data suggested that Foxm1 was critical for the maintenance of HSC quiescence and that in its absence, HSCs more easily entered the cell cycle.
Foxm1 loss reduces the survival of HSCs and HPCs under stress As cell survival contributes to the maintenance of HSCs and HPCs, we examined Foxm1-deficient and control HSCs and HPCs for evidence of apoptosis by staining cells with annexin V. We found that Foxm1 loss did not affect the frequency of apoptosis of LSK cells and HPCs from Foxm1-CKO mice (Supplementary Fig. 7a) . Notably, we found that the frequency of apoptosis was significantly higher in LSK cells and HPCs from Foxm1-CKO and Foxm1 fl/fl Mx1-Cre chimeric mice than in those from Foxm1 fl/fl chimeric mice (Supplementary Fig. 7b,c) .
As transplantation of HSCs exposes HSCs and HPCs to various stresses 33 , our studies suggested that loss of Foxm1 reduced the survival of HSCs and HPCs under stress.
Foxm1 deficiency affects multiple pathways in HSCs
To identify Foxm1-dependent genes and the molecular pathways involved in the regulation of HSC function, we performed global gene-expression profiling of LT-HSCs isolated from 2-month-old Foxm1-CKO mice and Foxm1 fl/fl control mice. We found that 70 genes had over-twofold differential expression in Foxm1-CKO HSCs relative to their expression in Foxm1 fl/fl HSCs ( Fig. 6a and Supplementary Table 2 ). The differentially expressed genes were classified into seven functional groups, including genes encoding products with nucleic acid-binding transcription factor activity, binding activity, catalytic activity and structural activity (Fig. 6b) . Accumulating evidence suggests a regulatory function for ribosomes in gene expression 34 . Deregulation of protein synthesis by altering ribosome function impairs HSC function 35 . Notably, genes encoding several ribosomal proteins, including Rpl38, Utp14a, Rpl29, Mrpl24 and Rpl21, had significantly higher expression in HSCs lacking Foxm1 (Foxm1-CKO) than in Foxm1-sufficient (Foxm1 fl/fl ) control HSCs (Supplementary Table 2 ). Next we used gene-set-enrichment analysis 36 to determine whether an a priori-defined set of genes showed significantly different expression in HSCs in the absence of Foxm1 than in the presence of Foxm1 by analyzing a data set with 20,000 transcripts. This analysis revealed that the set of genes downregulated in Foxm1-deficient HSCs showed enrichment for a gene set encoding products associated with cytokine signaling in the immune system (Fig. 6c, left) . Notably, genes targeted by AML1 (Runx1), a critical regulator of HSC self-renewal, were also downregulated in Foxm1-deficient HSCs (Fig. 6c, right) . Consistent with the observed increase in cycling HSCs in Foxm1-deficient mice, the set of genes upregulated in Foxm1-deficient HSCs showed enrichment for a gene set encoding products associated with progression through S phase (Fig. 6d, left) . E2F1 is a positive regulator of G1-S of the cell cycle 37 , and the set of genes upregulated in Foxm1-deficient HSCs showed enrichment for genes targeted by E2F1 (Fig. 6d, right) , which provided additional evidence for enhanced cell cycling in Foxm1-deficient HSCs. Thus, these Foxm1 deficiencymediated transcriptional changes indicated that the absence of Foxm1 perturbed multiple stem cell-maintenance mechanisms.
Nurr1 mediates Foxm1 function in regulating HSC quiescence
Among the genes significantly downregulated in Foxm1-deficient HSCs (Fig. 6a) , the nuclear receptor Nurr1 stood out due to its important role in the maintenance of HSC quiescence. Loss of a single allele of Nurr1 is sufficient to induce HSCs to enter into the cell cycle and proliferate 17 . This effect is associated with the downregulation of genes encoding cyclin-dependent kinase inhibitors, including p21 and p27, in Nurr1-null HSCs 17 . Notably, our expression profiling data (confirmed by quantitative RT-PCR; 
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A r t i c l e s genes encoding Nurr1, p21 (Cdkn1a) and p27 (Cdkn1b). In contrast, expression of the genes encoding p57 (Cdkn1c) and p16 (Cdkn2a) was similar in Foxm1-deficient (Foxm1-CKO) and Foxm1-sufficient (Foxm1 fl/fl ) HSCs (Fig. 6e) . Together these data suggested that deletion of Foxm1 promoted cell cycling of HSCs at the molecular level. The gene encoding cyclin B1 (Ccnb1), a protein associated with the G2-to-M transition, is a downstream target of Foxm1 in other cell types 7 . Our gene-expression data (confirmed by quantitative RT-PCR; Fig. 6e ) indicated that Ccnb1 was downregulated in Foxm1-deficient HSCs, consistent with our finding that the G2-to-M transition was delayed in these cells. To determine whether Foxm1 modulates Nurr1 expression through direct transcriptional activation, we searched for the consensus Foxm1-binding site T(G/A)TTT(G/A)TT (where '(G/A)' means G or A) 38 in the proximal promoter region of Nurr1. We identified two putative Foxm1-binding sites upstream of the Nurr1 transcription start site (Fig. 7a) . We next performed dual-luciferase reporter assays with cells expressing the wild-type Nurr1 promoter or a promoter with mutation of the predicted Foxm1-binding sites. The luciferase activity of a construct containing the wild-type binding site 1 was activated by Foxm1 expression, but a construct containing a mutated binding site 1 or a construct containing binding site 2 alone did not (Fig. 7b,c) ; this suggested that the integrity of consensus site 1 in the Nurr1 promoter was required for Foxm1-mediated activation of Nurr1 expression. A chromatin-immunoprecipitation assay of Lin − BM cells revealed that Foxm1 directly bound to site 1 but not site 2 of the Nurr1 promoter (Fig. 7d) .
To determine whether downregulation of Nurr1 was critical for the loss of quiescence seen in Foxm1-deficient LSK cells, we assessed the effect of enforced expression of Nurr1 on the quiescence of Foxm1 fl/fl Mx1-Cre LSK cells in vivo. In these experiments, Nurr1 was expressed under control of a modified tetracycline-responsive promoter 39 , in a lentivirus vector that allows doxycycline-controlled gene expression. We infected Foxm1 fl/fl and Foxm1 fl/fl Mx1-Cre BM cells with empty lentivirus expression vector or vector containing Nurr1 and transplanted the cells into the lethally irradiated recipient mice to generate chimeric mice. We induced Foxm1 depletion and expression of Nurr1 in these mice by treatment with poly(I:C) and doxycycline, respectively, at 6 weeks after transplantation. We confirmed induction of Nurr1 expression in BM cells from chimeric mice by immunoblot analysis (Supplementary Fig. 8a) . Notably, the frequency of quiescent cells was significantly greater among Nurr1-transduced Foxm1 fl/fl Mx1-Cre LSK cells than that among empty vector-transduced Foxm1 fl/fl control LSK cells in chimeric mice (Fig. 7e,f) . The frequency of LSK cells and LT-HSCs was higher among BM cells from Nurr1-transduced Foxm1 fl/fl Mx1-Cre chimeric mice than among empty vector-transduced Foxm1 fl/fl Mx1-Cre chimeric mice, even 2 weeks after the induction of Nurr1 expression (Fig. 7g) ; this indicated that Nurr1 expression prevented the depletion of LT-HSCs and LSK cells induced by the absence of Foxm1. In addition, the genes encoding p21 and p27 were upregulated by Nurr1 expression, which reversed the downregulation of the expression of these genes in Foxm1-deficient LSK cells (Supplementary Fig. 8b ). Together these data suggested that Nurr1 insufficiency mediated Foxm1 depletion-induced loss of quiescence in LSK cells.
Downregulation of FOXM1 in a subset of patients with MDS
To determine the function of Foxm1 in the cell-cycle regulation of human HSCs and HPCs, we investigated whether downregulation of FOXM1 expression in CD34 + hematopoietic cells from human umbilical cord blood would lead to the same perturbations in the cell cycle that we had observed in Foxm1-null mice. We downregulated FOXM1 expression in CD34 + cells from human cord blood through the use of short hairpin RNA (shRNA). Consistent with published results 40 , a large number of CD34 + HSCs were quiescent after several days of in vitro culture (Fig. 8a,b) . We observed more proliferation (frequency of cells in S phase) and fewer quiescent cells (frequency of cells in G0 phase) when FOXM1 expression was reduced by shRNA (Fig. 8a,b) . Thus, decreasing FOXM1 expression in these human cells reduced quiescence. Decreased HSC function contributes to the development of MDS, which is a clonal HSC disorder characterized by infective hematopoiesis 41 . By analyzing a published set of microarray data of CD34 + HSCs and HPCs from 183 patients with MDS with various cytogenetic abnormalities and 17 healthy control subjects 42 , 
we found that FOXM1 and NURR1 were downregulated in CD34 + cells from patients with MDS with deletion of chromosome 5q relative to their expression in cells from healthy control subjects (Fig. 8c) . Notably, reducing FOXM1 expression via shRNA in human primary CD34 + cells led to downregulation of NURR1 (Fig. 8d) . Our findings raised the possibility of a critical role for a Foxm1-mediated pathway in the pathogenesis of MDS with deletion of chromosome 5q via deregulation of HSC function in patients with this deletion.
DISCUSSION
In this study, we have identified a previously unrecognized role for Foxm1 in the maintenance of HSCs and HPCs. Using mouse models with conditional deletion of Foxm1, we have shown that Foxm1 was essential for maintaining the quiescence and self-renewal of HSCs in vivo and that it intrinsically regulated the proliferation of HSCs and HPCs but not their differentiation. We also have identified Nurr1 as an additional downstream effector of Foxm1 that was directly activated by Foxm1 and was able to mediate the function of Foxm1 in regulating HSC quiescence.
Foxm1 has been consistently reported as a 'pro-proliferation' factor in proliferating cells through its promotion of progression through the cell cycle 5 . However, some studies have suggested a role for Foxm1 in the self-renewal of stem cells. Foxm1 is involved in maintaining the pluripotency of embryonic stem cells 43 . Interestingly, deletion of Foxm1 in neural cortical stem cells and/or progenitor cells from cortical tissue at embryonic day 14.5 reduces their formation of the neurosphere in vitro, which indicates a possible role for Foxm1 in the self-renewal of neural stem cells and/or progenitor cells 44 . Foxm1 also regulates the self-renewal of glioma-initiating cells in vitro by promoting localization of β-catenin to the nucleus (and thus activation of its target genes) 45 . However, the in vivo role of Foxm1 in adult stem cells has not been characterized before, to our knowledge. Our findings have provided in vivo evidence that Foxm1 seems to have divergent functions in HSCs. We observed that inducing the loss of Foxm1 in HSCs of either embryos or adults (via either Tie2-Cre or Mx1-Cre, respectively) had an almost identical effect on the function of HSCs and HPCs, which suggested that Foxm1 intrinsically regulates the self-renewal and quiescence of HSCs in adults. Foxm1 is required for injury-induced regeneration of the liver, lung and pancreas in adults 5 . Our findings raise the possibility that the role of Foxm1 in tissue regeneration might be mediated in part by its effect on relevant tissue-specific stem cells.
Published studies have shown that Foxm1 stimulates proliferation by promoting entry into the S and M phases of the cell cycle 5 . In contrast, we observed here that Foxm1 increased the proliferation of HSCs and HPCs. In line with our observation that loss of Foxm1 promoted the proliferation of HSCs and HPCs, our expression profiling data showed that genes that are targets of E2F1, as well as other genes encoding products that that promote transition through the S phase, were significantly upregulated when Foxm1 was absent in HSCs, which provided molecular evidence for the observed promotion of the progression of HSCs through S phase. Moreover, loss of Foxm1 led to downregulation of Nurr1 and genes encoding cyclin-dependent kinase inhibitors, including p21 and p27. Of interest, published studies have shown that loss of even a single allele of Nurr1 markedly impairs the quiescence of HSCs and their capacity for self-renewal and is associated with downregulation of the genes encoding p21 and p27 in HSCs 17 . We found that ectopic expression of Nurr1 reversed the downregulation of the genes encoding p21 and p27 induced by deletion of Foxm1, which suggested that these effects are probably mediated by Nurr1. Finally, our studies indicated that Foxm1 activated Nurr1 expression by directly binding its promoter and that forced expression of Nurr1 reversed the loss of quiescence in Foxm1-deficient populations enriched for stem cells. Together these results suggest that Foxm1 regulates HSC quiescence through control of Nurr1-mediated downstream pathways. Nonetheless, analysis of global gene expression in Foxm1-deficient and Foxm1-sufficient LT-HSCs suggested that Foxm1 regulates the function of HSCs through multiple molecular pathways. Additional studies are needed to determine whether the other downstream pathways are important for mediating Foxm1 function in HSCs.
Several known downstream targets of Foxm1, including Sox2 and Bmi1, seem to be important for the self-renewal of neural stem cells 44 . However, we did not observe changes in the expression of Sox2 or Bmi1 in Foxm1-deficient HSCs relative to their expression in control HSCs. In addition, we did not detect significant changes in Foxm1-deficient HSCs in the expression of genes that are targets of β-catenin (regulated by Foxm1 in glioma-initiating cells 45 ). Thus, we conclude that Foxm1 regulates gene expression in a tissue-specific manner, perhaps to confer onto Foxm1 its divergent functions in various tissues.
The role of Foxm1 in the regulation of apoptosis is controversial 46 . We found that depletion of Foxm1 did not affect the apoptosis of HSCs or HPCs at steady state. However, the absence of Foxm1 induced apoptosis of HSCs and HPCs upon transplantation into chimeric mice, a condition that exposes HSCs and HPCs to various stresses 33 . These data indicate a role for Foxm1 in maintaining the survival of HSC or HPCs under conditions of cellular stress. (1) shFoxm1 (1) shFoxm1 (2) shFoxm1 ( Fig. 5f ) analyzing the quiescence of CD34 + cells transduced to express no shRNA (Ctrl) or shRNA targeting Foxm1 (either of two constructs: shFoxm1 (1) and shFoxm1 (2)) (numbers in quadrants as in Fig. 5f ). 
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The role of Foxm1 in MDS is unknown. By analyzing public databases, we found that the gene encoding Foxm1 and its downstream target NURR1 were both significantly downregulated in a subset of patients with MDS. More notably, reduced expression of FOXM1 promoted loss of quiescence and downregulated NURR1 expression in human primary CD34 + HSCs and/or HPCs. Thus, our data indicate a critical role for Foxm1 in maintaining human HSCs and/or HPCs and that deregulation of FOXM1 expression might contribute to human hematological malignant diseases such as MDS by affecting the function of HSCs and/or HPCs. In summary, we have provided functional and molecular evidence that Foxm1 acts a critical regulator of selfrenewal of adult HSCs through control of HSC quiescence and have provided evidence in support of a tissue-specific multi-faceted role for Foxm1 in cell-cycle regulation.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Mice and blood cell counts. For conditional deletion of Foxm1 in vivo, Foxm1 fl/fl mice were mated to Tie2-Cre or Mx1-Cre transgenic mice to generate Foxm1-CKO or Foxm1 fl/fl Mx1-Cre mice. Mx1-Cre expression was induced by three intraperitoneal injections of 6-10 µg (poly(I:C)) (GE Healthcare) per gram of body weight every second day for a total of three injections. Times after poly(I:C) injection are 'counted' from the third poly(I:C) injection. Peripheral blood samples were collected from the tail vein into tubes containing EDTA. Complete blood counts and differentials were obtained with a Hemavet 950FS (Drew Scientific). All animal research was approved by the University of Illinois at Chicago Institutional Animal Care and Use Committee.
Flow cytometry. Single-cell suspensions were prepared from BM (femurs and tibiae), spleen, thymus and peripheral blood. Red cells were lysed with ammonium-chloride-potassium (ACK) buffer. Cells were incubated for 20 min on ice with antibodies. The following fluorochrome-or biotin-conjugated antibodies to mouse molecules were used (all from eBioscience, except allophycocyanin-conjugated anti-CD150 (from BioLegend); all antibodies identified in Supplementary Table 3) : anti-Gr-1, anti-Ter119, anti-B220, anti-CD19, anti-IgM, anti-IL-7R and anti-CD3, for lineage markers; streptavidin-phycoerythrin (PE)-indodicarbocyanine (Cy5), PE-anti-Sca-1, allophycocyanin-indotricarbocyanine (Cy7)-anti-c-Kit, PE-Cy7-anti-CD48 and allophycocyanin-anti-CD150, for analysis of HSCs, LSK cells and HPCs; streptavidin-allophycocyanin-Cy7, PE-anti-Sca-1, allophycocyanin-anti-c-Kit and PE-Cy5-anti-Flt3, for analysis of LMPPs; streptavidin-allophycocyaninCy7, PE-anti-Sca-1, allophycocyanin-anti-c-Kit, PE-Cy7-anti-CD16/32 and eFluor 450-anti-CD34, for analysis of CMPs, GMPs, MEPs 47, 48 ; PE-anti-B220 and allophycocyanin-IgM, for analysis of B cells; PE-anti-Gr-1 and allophycocyanin-anti-Mac-1, for analysis of myeloid cells; allophycocyanin-anti-Ter119 and PE-anti-CD71, for analysis of erythroid cells; anti-CD4 and anti-CD8, for analysis of mature T cells; PE-Cy7-anti-CD41and allophycocyanin-anti-c-Kit, for analysis of megakaryocytes; PE-anti-F4/80 and allophycocyanin-anti-MAC, for analysis of macrophages; and allophycocyanin-Cy7-anti-CD45.2 or fluorescein isothiocyanate-anti-CD45.2 and PE-anti-CD45.1, for identification of donor cells in recipient mice.
For cell-cycle analysis, 5 × 10 6 BM cells were stained for the identification of HSCs, then cells were fixed with 1% formaldehyde in PBS, treated with 0.1% Triton X-100, stained with 5 µg/ml DAPI and analyzed on a Gallios flow cytometer. For cell-cycle analysis with Hoechst 33342 and Pyronin Y, BM cells were incubated for 45 min at 37 °C with 5 µg/ml Hoechst dye, and then were further incubated for 45 min at 37 °C with Hoechst dye and 1 µg/ml Pyronin Y. Cells were stained with 'cocktail' of antibodies to lineage markers (Supplementary Table 3) , and then the cells were stained with streptavidin-allophycocyanin-Cy7, fluorescein isothiocyanate-anti-Sca-1 and allophycocyanin-anti-c-Kit. For the detection of apoptosis, BM cells were stained with antibody conjugates, annexin V and DAPI.
Colony-forming assays. 6 × 10 4 BM cells from Foxm1 fl/fl or Foxm1-CKO mice were plated in triplicate in 35-mm tissue culture dishes containing Mouse Methylcellulose Complete Media (HSC007; R&D Systems). After 10 d of incubation at 37 °C in 5% CO 2 , granulocyte-erythroid-macrophagemegakaryocyte colonies, granulocyte-macrophage colonies, granulocyte colonies, macrophage colonies, and burst-forming unit-erythroid colonies were viewed with an inverted microscope and assigned scores. were obtained from recipient at 4 months after first transplantation and were transferred to a second set of lethally irradiated mice.
5-FU treatment. 5-FU was administrated to mice intraperitoneally at a dose of 150 mg per kg body weight, once per week for 3 weeks, and the survival of individual mice was monitored daily.
BrdU-incorporation assay. Mice were given intraperitoneal injection of 100 µl of 10 mg/ml BrdU (Sigma) 24 h before being killed for analysis. BM cells were stained with fluorochrome-conjugated antibodies (Supplementary Table 3 ), followed by fixation and permeabilization with Cytofix/Cytoperm (BD Biosciences), treatment with DNase I (Sigma), and staining with a BrdUspecific antibody (Bu20a; eBioscience) according to the instruction manual of the BrdU flow kit (BD Pharmingen). The cells were analyzed by flow cytometry with a CyAn ADP flow cytometer.
Microarray and bioinformatics analysis. Total RNA was extracted from sorted LT-HSC cells (CD150 + CD48 − LSK) from 2-month0old Foxm1 fl/fl and Foxm1-CKO mice with and RNeasy Micro Kit (Qiagen) and was amplified with the Ovation Pico WTA System V2 (NuGEN Technologies). Labeled cDNA was hybridized to a Mouse Gene 1.0 ST Array (Affymetrix). Chip quality was analyzed and determined with Affymetrix GCOS software. All RNA samples and arrays used in this study passed the established quality criteria. The raw data were normalized with the R/Bioconductor software package 'affy' 49 . Gene-set-enrichment analysis was performed with GSEA v2.0 software (available from the Broad Institute).
RNA extraction and quantitative RT-PCR analysis. Total RNA was isolated with an RNeasy Mini Kit or Rneasy Micro Kit (Qiagen). cDNA as reversetranscribed from total RNA with the SuperScript III First-Strand Synthesis System (Life Technologies). Then, cDNA was subjected to real-time PCR with SYBR Green Supermix (Bio-Rad) in an iCycler iQ Real Time PCR Detection System (Bio-Rad). All primers are listed in Supplementary Table 4. All samples were run in triplicate. Amplification of Actb (encoding β-actin) was used for sample normalization.
Chip assay. Lin − BM cells from wild-type mice were fixed for 10 min at 37 °C with 1% formaldehyde, the reaction was stopped by the addition of glycine to a final concentration of 125 mM, followed by incubation for 5 min at 25 °C. Cells were washed two times with cold PBS and were lysed in Szak RIPA buffer (150 mM Nacl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0, 5 and mM EDTA) with a protease inhibitor 'cocktail' . After cell lysis, crosslinked chromatin was sheared with a sonicator. Then, 5 µg of anti-Foxm1 (K-19; Santa Cruz Biotechnology) or control IgG (sc-2027; Santa Cruz Biotechnology) were used for immunoprecipitation. After elution of DNA from precipitated immunocomplexes, quantitative real-time PCR analysis was performed with specific primers (sequences, Supplementary Table 4) for amplification of site 1and site 2 in the Nurr1 promoter region, and a control site 8 kilobases downstream of the final exon of Ccnb1 (encoding cyclin B1).
Luciferase reporter assay. Two putative Foxm1-binding sites were identified by searching of the consensus Foxm1-binding site [T(G/A)TTT(G/A)TT] upstream of the Nurr1 transcription start site. The corresponding genomic region that included these putative binding sites was amplified by PCR from wild-type C57BL/6 mouse genomic DNA (primer sequences, Supplementary Table 4), then was subsequently subcloned into a pGL3-Basic luciferase reporter vector and called 'Site 1-pGL3' or 'Site 2-pGL3' . 'Mut-Site 1-pGL3' was generated by site-directed mutagenesis of the Foxm1-binding site in Site 1-pGL3 (primer sequences, Supplementary Table 4) . Site 1-pGL3, Site 2-pGL3 or Mut-Site 1-pGL3 was transfected into 293T cells through the use of the lipid-based 293T TransIT reagent (Mirus Bio), together with either MigR1 (empty vector) or MigR1 vector expressing Foxm1, as well as phRL-SV40 vector as an internal control. Cells were collected 36 h after transfection and both luciferase activities were assessed with the Dual-Luciferase reporter assay system according to the manufacturer's instructions (Promega). 
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